ArticleOncogene2015
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.
Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy.Journal of translational medicine · 2025Article
- Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.Cancer genomics & proteomics · 2023Article
- Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer.Journal of experimental & clinical cancer research : CR · 2023Article
- Identifying potential circulating miRNA biomarkers for the diagnosis and prediction of ovarian cancer using machine-learning approach: application of Boruta.Frontiers in digital health · 2023Article
- Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022Article
- Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.Journal for immunotherapy of cancer · 2022Article
- Characterizing the mutational landscape of MM and its precursor MGUS.American journal of cancer research · 2022Article
- SelectedBioMed research international · 2021Article
- MiR-3121-3p promotes tumor invasion and metastasis by suppressing Rap1GAP in papillary thyroid cancerAnnals of translational medicine · 2020Article
- Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.Cancer research and treatment · 2020Article
- Effect of variation in miRNA-binding site (rs8176318) of the BRCA1 gene in breast cancer patientsTurkish journal of medical sciences · 2019Article
- The human ATF1 rs11169571 polymorphism associated with risk of nasopharyngeal carcinoma in Southern Chinese populations.Cancer medicine · 2019Article
- A Germline Mutation in the BRCA1 3’UTR Variant Predicts Susceptibility to Breast Cancer in a Saudi Arabian PopulationAsian Pacific journal of cancer prevention : APJCP · 2018Article
- E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx.Molecular carcinogenesis · 2017Article
- Genome-Wide microRNA Binding Site Variation between Extinct Wild Aurochs and Modern Cattle Identifies Candidate microRNA-Regulated Domestication Genes.Frontiers in genetics · 2017Article
- Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.European journal of human genetics : EJHG · 2016Article
- Role of non-coding sequence variants in cancer.Nature reviews. Genetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
Ovarian cancer is a major cause of cancer deaths, yet there have been few known genetic risk factors identified, the best known of which are disruptions in protein coding sequences (BRCA1 and 2). Recent findings indicate that there are powerful genetic markers of cancer risk outside of these regions, in the noncoding mRNA control regions. To identify additional cancer-associated, functional non-protein-coding sequence germline variants associated with ovarian cancer risk, we captured DNA regions corresponding to all validated human microRNAs and the 3' untranslated regions (UTRs) of ~6000 cancer-associated genes from 31 ovarian cancer patients. Multiple single-nucleotide polymorphisms in the 3'UTR of the vascular endothelial growth factor receptor/FLT1, E2F2 and PCM1 oncogenes were highly enriched in ovarian cancer patients compared with the 1000 Genome Project. Sequenom validation in a case-control study (267 cases and 89 controls) confirmed a novel variant in the PCM1 3'UTR is significantly associated with ovarian cancer (P=0.0086). This work identifies a potential new ovarian cancer locus and further confirms that cancer resequencing efforts should not ignore the study of noncoding regions of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.